Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Allena presents initial phase I data on ALLN-346 for hyperuricemia

Dec. 1, 2020

Experimental aorta transplantation ameliorates uremic vascular calcification in rats

Nov. 12, 2020

EZH2 as novel therapeutic target for chronic kidney disease

Nov. 12, 2020

Janssen Pharmaceutica discloses BARK1 inhibitors

Nov. 11, 2020

Phase III CARDINAL study of bardoxolone in Alport syndrome meets primary endpoint

Nov. 10, 2020

Phase III trial of Nefecon in primary IgAN meets key endpoints

Nov. 9, 2020

CaMK4 as potential target to slow cyst growth in PKD

Nov. 9, 2020

SYNB-8802 consumes GI oxalate in animals with acute hyperoxaluria

Nov. 6, 2020

Synlogic advances SYNB-8802 into phase I study for treatment of enteric hyperoxaluria

Nov. 5, 2020

Phase III results for molidustat in patients with renal anemia undergoing dialysis

Nov. 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...